Quick answers
- What is Flortaucipir F-18 used for?
- The FDA-approved label (Tauvid, Eli Lilly and Company, December 30, 2025) says: “TAUVID is indicated for use with positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD). …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Flortaucipir F-18 have a boxed warning?
- No. None of the 1 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Flortaucipir F-18?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Flortaucipir F-18 been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Flortaucipir F-18?
- 1 company lists prescription products of Flortaucipir F-18 in the FDA NDC Directory, including Eli Lilly and Company.
What Flortaucipir F-18 is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
TAUVID is indicated for use with positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD). …
— FDA label: Tauvid, Eli Lilly and Company, effective December 30, 2025. Read the full label on DailyMed →
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
Forms and how it is given
| Dosage forms | Injection, solution |
|---|---|
| Route | Intravenous |
| Prescription products | 1 in the FDA NDC Directory |
| Brand names | Tauvid |
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Eli Lilly and Company1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA212123 TAUVID | Avid Radiopharms Inc | May 28, 2020 | 2, latest February 5, 2024 2024: Labeling · 2022: Manufacturing (CMC) |
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| SPL set ID of the quoted label | b483abad-5230-462a-adfb-1a65160f01d0 |
|---|---|
| FDA labels (SPL) | 1 |
| FDA applications | NDA212123 |
| Active ingredients (FDA) | FLORTAUCIPIR F-18 |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Tauvid, Eli Lilly and Company, effective December 30, 2025; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →